Patents by Inventor Jorg Eder

Jorg Eder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uses of piperidinyl-indole derivatives
    Patent number: 12285422
    Abstract: The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: April 29, 2025
    Assignee: Novartis AG
    Inventors: Jorg Eder, Richard Alexander Harrison, Boerje Haraldsson, Anna Svenja Shchubart Wellensiek
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20240067750
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: January 20, 2023
    Publication date: February 29, 2024
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • Uses of piperidinyl-indole derivatives
    Patent number: 11723901
    Abstract: The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: August 15, 2023
    Assignee: Novartis AG
    Inventors: Jörg Eder, Richard Alexander Harrison, Boerje Haraldsson, Anna Svenja Schubart
  • NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES
    Publication number: 20220152011
    Abstract: The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Inventors: Jorg EDER, Richard Alexander HARRISON, Boerje HARALDSSON, Anna Svenja WELLENSIEK SCHUBART
  • NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES
    Publication number: 20200338059
    Abstract: The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).
    Type: Application
    Filed: August 30, 2018
    Publication date: October 29, 2020
    Inventors: Jörg EDER, Richard Alexander HARRISON, Boerge HARALDSSON, Anna Svenja SCHUBART
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20200115468
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 16, 2020
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • Factor XI antibodies and methods of use
    Patent number: 10465011
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: November 5, 2019
    Assignee: Novartis AG
    Inventors: Jorg Eder, Stefan Ewert, Ulrich Hassiepen, Yasser Khder, Lorenz Mayr, Samu Melkko, Nikolaus Schiering
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20180355056
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 13, 2018
    Applicant: NOVARTIS AG
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20170022292
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: January 26, 2017
    Applicant: NOVARTIS AG
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
    Patent number: 7645760
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: January 12, 2010
    Assignee: Novartis AG.
    Inventors: Birgit Bollbuck, Jorg Eder, Richard Heng, Laszio Revesz, Achim Schlapbach, Rudolf Walchli
  • 2-aminopyrimidine derivatives and their medical use
    Patent number: 7615562
    Abstract: A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: November 10, 2009
    Assignee: Novartis AG
    Inventors: Birgit Bollbuck, Alastair DenholmMritain, Jörg Eder, René Hersperger, Philipp Janser, Lászlo Révész, Achim Schlapbach, Rudolf Wálchi
  • 2-Aminopyrimidine derivatives and their medical use
    Publication number: 20070043048
    Abstract: A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.
    Type: Application
    Filed: April 8, 2004
    Publication date: February 22, 2007
    Inventors: Birgit Bollbuck, Alastair DenholMritain, Laszlo Revesz, Achim Schlapbach, Rudolf Walchli, Jorg Eder, Rene Hersperger, Philipp Janser
  • 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
    Publication number: 20060173004
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.
    Type: Application
    Filed: October 24, 2003
    Publication date: August 3, 2006
    Inventors: Birgit Bollbuck, Jorg Eder, Richard Heng, Laszlo Revesz, Achim Schlapbach, Rudolf Walchli